LYTIX Share Price Performance
NOK 9.00
3.20 (55.17%)
Price NOK 9.00
Share Pricen/a
Lytix Biopharma AS Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
LYTIX Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Lytix Biopharma AS Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 12, 2026
- -0.93
- 100.00%
- -19,424.67%
- 0%
About LYTIX
- Founded
- 2003
- Employees
- n/a
- CEO
- WebsiteView website
Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of LTX-315 for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma AS was founded in 2003 and is based in Oslo, Norway.
